Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Krista Fogarty is Principal Accounting Officer at Lipocine. OQRO lists 1 transaction filed with the SEC under this name, the latest on Dec 19, 2025, each linked to the official Form 4.
Principal Accounting Officer
Disclosures on record
1
Companies involved
1
LipocineLPCN
Dec 18, 202521Kdisclosed Dec 19
DetailsOfficial recordKrista Fogarty bought shares on the open market in 2022, and has not bought since 2022.
Krista Fogarty reported 1 open-market purchase and 0 sales since 2022; purchases in 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $11K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Krista Fogarty bought shares on the open market in 2022, and has not bought since 2022.
In SEC filings since 2022: the latest open-market purchase is from 2022; no open-market sale is on record.
Lipocine (LPCN), from 2022 to 2022: 1 purchase and 0 sales.
Krista Fogarty reported 1 open-market purchase and 0 sales here, 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
